Portal de Periódicos da CAPES

Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects

2007; Lippincott Williams & Wilkins; Volume: 27; Issue: 9 Linguagem: Inglês

10.1161/atvbaha.106.136853

1524-4636

Michiko Itoh, Takayoshi Suganami, Noriko Satoh, Kanami Tanimoto-Koyama, Xunmei Yuan, Miyako Tanaka, Hiroyuki Kawano, Takashi Yano, Seiichiro Aoe, Motohiro Takeya, Akira Shimatsu, Hideshi Kuzuya, Yasutomi Kamei, Yoshihiro Ogawa,

Regulation of Appetite and Obesity

Objectives— Fish oil rich in n-3 polyunsaturated fatty acids (PUFAs) or n-3 PUFAs have been shown to reduce the incidence of coronary heart disease. Here we investigated the effect of highly purified eicosapentaenoic acid (EPA) on production of adiponectin, the only established antiatherogenic and antiinflammatory adipocytokine, in rodent models of obesity and human obese subjects. Methods and Results— We demonstrated that EPA increases adiponectin secretion in genetically obese ob/ob mice and high-fat diet–induced obese mice. In the in vitro coculture of adipocytes and macrophages, EPA reversed the coculture-induced decrease in adiponectin secretion at least in part through downregulation of tumor necrosis factor-α in macrophages. We also showed significant increase in plasma adiponectin concentrations in human obese subjects after a 3-month treatment with EPA (1.8 g daily). Multivariate regression analysis revealed that EPA treatment is the only independent determinant of plasma adiponectin concentrations. Conclusion— This study demonstrates that EPA increases adiponectin secretion in rodent models of obesity and human obese subjects, possibly through the improvement of the inflammatory changes in obese adipose tissue. Because EPA has reduced the risk of major coronary events in a large-scale, prospective, randomized clinical trial, this study provides important insight into its therapeutic implication in obesity-related metabolic sequelae.